| アブストラクト | PURPOSE: Studies on COVID-19 mortality during the Omicron-predominant wave have focused primarily on the inpatient/emergency room setting, and real-world data including both inpatients and outpatients are lacking. METHODS: Patients diagnosed with COVID-19 (n = 27,440,148) or influenza (n = 8,179,641) from January 2020 to April 2023 were identified using nationwide claims data in Japan. Patients with COVID-19 in the Omicron-predominant wave were compared with their counterparts in earlier waves, and a subset of the former group (May 2022-April 2023) was compared with patients with influenza as controls. RESULTS: The mortality rates (average number of deaths/cases per week) of COVID-19 decreased over time, being 2.7% (169/6312), 2.1% (397/18,754), 0.7% (195/28,273), and 0.4% (1613/378,848) in the wild-type-, Alpha-, Delta-, and Omicron-predominant waves, respectively. However, the number of deaths increased substantially in the Omicron-predominant wave, especially among the elderly (e.g., in the Delta- and Omicron-predominant waves, the average numbers of deaths/cases per week were < 1/5527 (< 0.01%) and 4/105,763 (< 0.01%) respectively, in patients aged 0-19, versus 101/925 (10.9%) and 1212/20,771 (5.8%), respectively, in patients aged >/= 80). The mortality rate was lower for patients with COVID-19 than in those with influenza among those aged </= 39 years but higher among those aged >/= 40 years. CONCLUSIONS: In the Omicron-predominant wave, the mortality rate of COVID-19 decreased, but the number of patients increased, leading to a substantial increase in the number of deaths, especially among the elderly. The mortality rate of COVID-19 was higher than that of influenza in the elderly but not in the young, highlighting the need for age-specific interventions. |
|---|
| ジャーナル名 | Pneumonia (Nathan Qld.) |
|---|
| Pubmed追加日 | 2025/2/5 |
|---|
| 投稿者 | Miyashita, Koichi; Hozumi, Hironao; Furuhashi, Kazuki; Nakatani, Eiji; Inoue, Yusuke; Yasui, Hideki; Suzuki, Yuzo; Karayama, Masato; Enomoto, Noriyuki; Fujisawa, Tomoyuki; Inui, Naoki; Ojima, Toshiyuki; Suda, Takafumi |
|---|
| 組織名 | Second Division, Department of Internal Medicine, Hamamatsu University School of;Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, 431-3192, Japan.;hozumi@hama-med.ac.jp.;Department of Biostatistics and Data Science, Graduate School of Medical Science,;Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601,;Japan.;Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School;of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, 431-3192, Japan.;Department of Community Health and Preventive Medicine, Hamamatsu University;School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, 431-3192, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39905566/ |
|---|
